Industry Educational Session - Mind the gap: What’s driving third-line treatment decisions in lenalidomide-refractory multiple myeloma? [Menarini Stemline promotional symposium] - Sponsored by Menarini
Tracks
-
| Monday, April 28, 2025 |
| 5:30 PM - 6:15 PM |
| Carron 2 |
Details
Join us for a dynamic and thought-provoking promotional symposium, organised by Menarini Stemline. This engaging session will dive into the critical discussion of optimising treatment strategies for lenalidomide-refractory myeloma. Discover why it’s essential to evaluate all third-line options to maximise patient outcomes. Don’t miss this opportunity to gain expert insights, challenge perspectives, and be part of a vital conversation shaping the future of myeloma care.
Speaker
Prof. Gordon Cook
Professor of Haematology
University of Leeds
Professor of Haematology, Clinical Director (Haematology) and Honorary Consultant Haematologist, Leeds Institute of Clinical Trial Research, University of Leeds, and Leeds Cancer Centre, Leeds Teaching Hospitals Trust.
Dr. Ceri Bygrave
Consultant Haematologist
Cardiff and Vale UHB
Consultant Haematologist and Myeloma Lead, University Hospital of Wales, Cardiff. Director of Research and Development, Cardiff and Vale Haematology Department, Chair of the UK Myeloma Society.
Dr. Joshua Richter
Associate Professor 'Hematology and Medical Oncology
Mount Sinai
Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. Director of Multiple Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai.
